An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain

NCT00089557 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114

Conditions

  • Herpes Zoster
  • Neuralgia
  • Pain
  • HIV Infections
  • Peripheral Nervous System Diseases
  • Diabetic Neuropathies
  • Diabetes Mellitus
  • Polyneuropathies

Interventions

DRUG

Capsaicin Dermal Patch

Sponsors & Collaborators

  • NeurogesX

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089557 on ClinicalTrials.gov